Treatment results of venous thromboembolism with dalteparin in patients with multiple myeloma undergoing anti-myeloma chemotherapeutic agents

e198 the occurrence of VTE), significant conversion of d-dimer from 2.2 0.4 mg/L to 11.8 1.6 mg/L (P <0.001) was observed. At the time of data analysis, 7 patients are in dalteparin therapy and 37 patients finished dalteparin therapy with a median duration of 4.1 months (range, 2.7-8.4), and 4 patients early discontinued due to death (n1⁄43) and major bleeding (n1⁄41). With the improvement of clinical symptoms, d-dimer was decreased from 10.9 0.4 mg/L to 1.9 0.6 mg/L at 1 month after the initiation of dalteparin therapy. After a median follow-up of 8.7 months (range, 0.7-34.9) since a first episode of VTE, 5 patients showed the recurrence of VTE (the cumulative incidence; 18.3 8.1%). Major bleeding events were observed in 3 patients and one patient with nonfatal intracranial bleeding discontinued dalteparin therapy. Conclusion: Our study demonstrated the clinical outcome of anticoagulant therapy with dalteparin seems to be promising for the treatment of VTE in MM. In particular, the significant change of d-dimer was observed before occurrence of VTE and after dalteparin treatment in MM patients, suggesting the usefulness of d-dimer testing as a surrogate marker for VTE.